Formulation: A solid
Formal Name: N-((2S,3R,E)-1-(((2R,3R,4R,5S,6R)-5-(((2S,3R,4R,5R,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-(((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-hydroxyoctadec-4-en-2-yl)octadecanamide-d3
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C54H98D3NO18
Formula Weight: 1055,4
Shelf life (days): 1460
Notes: C18 Globotriaosylceramide-d3 is intended for use as an internal standard for the quantification of C18 globotriaosylceramide by GC- or LC-MS. C18 globotriaosylceramide is an endogenous sphingolipid that accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A.{41495} As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1537]
English
Deutsch
